SKYE insider transaction filings
Skye Bioscience, Inc. — 33 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen SKYE transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Schwab Andrew J. — Director, 10% owner | Sale (S): 45,090 @ $0.38 · Sale (S): 1,830 @ $0.38 · Sale (S): 253,080 @ $0.38 · Sale (S): 10,255 @ $0.35 · Sale (S): 409 @ $0.35 · Sale (S): 57,476 @ $0.35 · +3 more | EDGAR |
| 2026-08-20 | 4 | 5AM Partners VII, LLC — 10% owner 5AM Ventures VII, L.P. — 10% owner 5AM Partners II, LLC — 10% owner 5AM Ventures II LP — 10% owner 5AM CO-INVESTORS II LP — 10% owner DIEKMAN JOHN D — 10% owner PARMAR KUSH — 10% owner ROCKLAGE SCOTT M — 10% owner | Sale (S): 45,090 @ $0.38 · Sale (S): 1,830 @ $0.38 · Sale (S): 253,080 @ $0.38 · Sale (S): 10,255 @ $0.35 · Sale (S): 409 @ $0.35 · Sale (S): 57,476 @ $0.35 · +3 more | EDGAR |
| 2026-08-07 | 4 | DHILLON PUNIT — Chief Executive Officer, Director | Grant/award (A): 1,090,000 @ $0 | EDGAR |
| 2026-04-02 | 4 | Smith Karen L. — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Twitty Christopher — Chief Scientific Officer | Grant/award (A): 17,004 (derivative) · Disposition to issuer (D): 17,004 (derivative) · Grant/award (A): 75,000 (derivative) · Disposition to issuer (D): 75,000 (derivative) · Grant/award (A): 7,100 (derivative) · Disposition to issuer (D): 7,100 (derivative) · +6 more | EDGAR |
| 2026-04-02 | 4 | Jenkins Annalisa — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Charych Deborah H. — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Grayson Paul A. — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Schwab Andrew J. — Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Diep Tuan Tu — Chief Operating Officer | Grant/award (A): 150,000 (derivative) · Disposition to issuer (D): 150,000 (derivative) · Grant/award (A): 9,194 (derivative) · Disposition to issuer (D): 9,194 (derivative) · Grant/award (A): 22,021 (derivative) · Disposition to issuer (D): 22,021 (derivative) · +8 more | EDGAR |
| 2026-04-02 | 4 | DHILLON PUNIT — Chief Executive Officer, Director | Grant/award (A): 250,000 (derivative) · Disposition to issuer (D): 250,000 (derivative) · Grant/award (A): 36,000 (derivative) · Disposition to issuer (D): 36,000 (derivative) · Grant/award (A): 12,360 (derivative) · Disposition to issuer (D): 12,360 (derivative) · +8 more | EDGAR |
| 2026-02-09 | 4 | Schwab Andrew J. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Grayson Paul A. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Smith Karen L. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | ARSENAULT KAITLYN — Chief Financial Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Twitty Christopher — Chief Scientific Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Charych Deborah H. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Jenkins Annalisa — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Diep Tuan Tu — Chief Development Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | Arora Puneet S. — Chief Medical Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | DHILLON PUNIT — Chief Executive Officer, Director | Grant/award (A): 280,000 (derivative) @ $0 | EDGAR |
| 2025-08-22 | 4 | Schwab Andrew J. — Director, 10% owner | Sale (S): 58,642 @ $3.57 · Sale (S): 2,314 @ $3.57 · Sale (S): 163,979 @ $3.42 · Sale (S): 6,470 @ $3.42 | EDGAR |
| 2025-08-22 | 4 | 5AM Partners VII, LLC — 10% owner 5AM Ventures VII, L.P. — 10% owner 5AM Partners II, LLC — 10% owner 5AM Ventures II LP — 10% owner 5AM CO-INVESTORS II LP — 10% owner DIEKMAN JOHN D — 10% owner PARMAR KUSH — 10% owner ROCKLAGE SCOTT M — 10% owner | Sale (S): 58,642 @ $3.57 · Sale (S): 2,314 @ $3.57 · Sale (S): 163,979 @ $3.42 · Sale (S): 6,470 @ $3.42 | EDGAR |
| 2025-02-28 | 4/A | ARSENAULT KAITLYN — Chief Financial Officer | Sale (S): 190 @ $5.55 · Sale (S): 43,026 @ $4.99 | EDGAR |
| 2025-02-26 | 4 | Schwab Andrew J. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | ARSENAULT KAITLYN — Chief Financial Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Jenkins Annalisa — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Grayson Paul A. — Director | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Smith Karen L. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Charych Deborah H. — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Diep Tuan Tu — Chief Development Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | Arora Puneet S. — Chief Medical Officer | Grant/award (A): 38,000 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | DHILLON PUNIT — Chief Executive Officer, Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Skye Bioscience, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-20 | 8-K/A | 3.03 — Material Modification to Rights of Security Holders | EDGAR |
| 2026-08-19 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-29 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-04-06 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-04-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SKYE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →